Survivorship
Conditions
Keywords
survival, esophgeal cancer
Brief summary
In this retrospective study, we analyzed data from the Sichuan Cancer Hospital & Institute Esophageal Cancer Case Management Database (SCH-ECCM Database) from January 2010 to December 2017. Our study focused on examining the clinicopathological characteristics, lymph node removal at each station, and treatment details of patients with esophageal squamous cell carcinoma (ESCC) who underwent esophagectomy. Using this data, we developed a prediction model for OS by considering a combination of clinical characteristics and details of lymphadenectomy variables.
Detailed description
In this retrospective study, we analyzed data from the Sichuan Cancer Hospital & Institute Esophageal Cancer Case Management Database (SCH-ECCM Database) from January 2010 to December 2017. Our study focused on examining the clinicopathological characteristics, lymph node removal at each station, and treatment details of patients with esophageal squamous cell carcinoma (ESCC) who underwent esophagectomy. Using this data, we developed a prediction model for OS by considering a combination of clinical characteristics and details of lymphadenectomy variables. Additionally, the receiver operating characteristic curve demonstrated an area under the curve greater than 0.7 at 1, 3, and 5 years in both the verification and training groups. Furthermore, Kaplan-Meier (K-M) curves showed that our model effectively distinguished between high- and low-risk groups (p \< 0.01).
Interventions
OTHERThis was an observational study without any intervention
This was an observational study without any intervention
Sponsors
Yongtao Han
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Inclusion criteria
* Patients underwent esophagectomy at our hospital.
Exclusion criteria
* pathology confirmed a non-squamous cell carcinoma, * the tumor was located outside of the thoracic region, * R1/R2 resection was performed indicating incomplete tumor removal, * evidence of distant tumor metastasis was observed, or * they underwent preoperative neoadjuvant therapy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Survival | April 2022-April 2024 | Overall survival (OS) was defined as the time from the month and year of surgery until death or the last follow-up in April 2022. |
Countries
China
Outcome results
None listed